

### Maple-Brown Abbott Asian Dividend Growth Fund update

The Maple-Brown Abbott Asian Dividend Growth Fund ARSN 649 191 186 (**Fund**) Product Disclosure Statement (**PDS**) and Additional Information Booklet (**AIB**) dated 24 September 2021, issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 (**MBA**) is updated in accordance with this document.

This update should be read together with the PDS and AIB available at [maple-brownabbott.com.au/dividend-growth-fund](http://maple-brownabbott.com.au/dividend-growth-fund) or by calling 1300 097 995. Information in the PDS and AIB is subject to change and may be updated from time to time. *ASIC Corporations (Updated Product Disclosure Statements) Instrument 2016/1055* permits such update to be made via the MBA website where the change is not materially adverse.

**Effective 28 February 2022, the PDS and AIB are updated as follows:**

1. The PDS is updated to remove the following paragraph in section 1 'About Maple-Brown Abbott Limited', on page 2:

*Maple-Brown Abbott (Asia) Pty Limited ACN 119 987 923 (MBA Asia) has been appointed as the investment manager of the Fund and receives fees from us for performing this role from the management fee we charge the Fund. MBA Asia has a high conviction strategy focused on stock selection, driven by in-depth analysis from their experienced team of investment professionals. They focus on equities across the Asian region.*

2. The AIB is updated to remove the following paragraph in section 7 'Other Information, Consents' on page 15:

*Maple-Brown Abbott (Asia) Pty Limited has consented to being named in the PDSs for the Maple-Brown Abbott Asian Dividend Growth Fund and the Maple-Brown Abbott Asian Investment Trust and this AIB, and to statements being included based on information they have provided, in the form and context they have been included. They have not withdrawn their consent before the date of these documents.*

3. The PDS and AIB are updated to replace all references to 'MBA Asia' with 'Maple-Brown Abbott'.

MBA does not consider these changes to be materially adverse as they (i) will not result in any change to the management personnel that undertake the day-to-day management of the Fund (ii) do not impact the rights of unitholders or the terms of investment in the Fund (including in relation to the investment objective or strategy of the Fund) and (iii) will not result in any change to the fees or costs paid by unitholders.